Larimar Therapeutics, Inc. (LRMR) is in Healthcare, Biotechnology, based in United States, listed on NasdaqGM. Market cap 280.48M USD. 52-week range 2.61 to 6.42 USD. Data as of 2026-10-09.
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal disease. The company is based in Bala Cynwyd, Pennsylvania.